Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022–2024: a nationwide cross-sectional study of over 1.6 million cases

Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia (CAP), accounting for 10–40% of cases in children. In China, the high prevalence of macrolide-resistant MP (MRMP) and recurrent MP epidemics place a significant burden on the healthcare system. Leveraging data from over 1....

Full description

Saved in:
Bibliographic Details
Main Authors: Yamin Sun, Pei Li, Ronghua Jin, Yaoming Liang, Jiale Yuan, Zhongxin Lu, Junrong Liang, Yingmiao Zhang, Hongyu Ren, Yuanyuan Zhang, Jianchun Chen, Yun Huang, Chuixu Lin, Yinghua Li, Jianfeng Zhou, Xi Wang, You Li, Senzhong Huang, Jianguo Xu, Tian Qin
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Emerging Microbes and Infections
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2025.2482703
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia (CAP), accounting for 10–40% of cases in children. In China, the high prevalence of macrolide-resistant MP (MRMP) and recurrent MP epidemics place a significant burden on the healthcare system. Leveraging data from over 1.6 million cases, this study provides a comprehensive analysis of the epidemiological characteristics of MP across China. Seasonal patterns analysis revealed three distinct transmission zones in China. Transmission Zone 1 exhibited two annual epidemic peaks, while Zones 2 and 3 showed a single annual peak of distinct timings. Notably, winter travel to popular tourist destinations appears to influence MP infection patterns in China. Age- and sex- specific analysis indicated male newborns aged [0–1) years face a 1.67 times higher risk of MP infection compared to females. Conversely, females aged [23–38) years have a higher infection risk, likely due to their caregiving roles. The proportion of MRMP surged from 80.00% to 93.02% between July 2023 and May 2024, with a median growth rate of 10.21%. This rapid increase contrasts sharply with the modest 5.3% rise observed from 2011 to 2019, and we attribute this escalation in part to the growing prevalence of the T1-3R clade strain in China. These findings have important implications for the identification of high-risk population, place, and time for more targeted efforts of prevention and treatment. Furthermore, the rapidly increased proportion of MRMP in the 2023–2024 season raises a concerning signal regarding antibiotic use.
ISSN:2222-1751